Citation: Kim Lawson. Is there a role for melatonin in fibromyalgia?[J]. AIMS Molecular Science, 2019, 6(4): 73-86. doi: 10.3934/molsci.2019.4.73
[1] |
Lawson K (2017) Emerging pharmacological strategies for the treatment of fibromyalgia. World J Pharmacol 6: 1–10. doi: 10.5497/wjp.v6.i1.1
![]() |
[2] | Borchers AT, Gershwin ME (2016) Fibromyalgia: a critical and comprehensive review. Clinic Rev Allerg Immunol 49: 100–151. |
[3] |
Clauw DJ (2014) Fibromyalgia: a clinical review. JAMA 311: 1547–1555. doi: 10.1001/jama.2014.3266
![]() |
[4] |
Üçeyler N, Zeller D, Kahn AK, et al. (2013) Small fibre pathology in patients with fibromyalgia syndrome. Brain 136: 1857–1867. doi: 10.1093/brain/awt053
![]() |
[5] | Wolfe F, Smythe HA, Yunus MB, et al. (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160–172. |
[6] |
Macfarlane GJ, Kronisch C, Dean LE, et al. (2017) EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 76: 318–328. doi: 10.1136/annrheumdis-2016-209724
![]() |
[7] |
Wolfe F, Clauw DJ, Fitzcharles MA, et al. (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 62: 600–610. doi: 10.1002/acr.20140
![]() |
[8] |
Queiroz LP (2013) Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 17: 356. doi: 10.1007/s11916-013-0356-5
![]() |
[9] |
Sluka KA, Clauw DJ (2016) Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience 338: 114–129. doi: 10.1016/j.neuroscience.2016.06.006
![]() |
[10] |
Fayed N, Garcia-Campayo J, Magallón R, et al. (2010) Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther 12: R134. doi: 10.1186/ar3072
![]() |
[11] |
Pyke TL, Osmotherly PG, Baines S (2017) Measuring glutamate levels in the brains of fibromyalgia patients and a potential role for glutamate in the pathophysiology of fibromyalgia symptoms: a Systematic Review. Clin J Pain 33: 944–954. doi: 10.1097/AJP.0000000000000474
![]() |
[12] |
Wood PB, Schweinhardt P, Jaeger E, et al. (2007) Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 25: 3576–3582. doi: 10.1111/j.1460-9568.2007.05623.x
![]() |
[13] |
Vanecek J (1998) Cellular mechanisms of melatonin action. Physiol Rev 78: 687–721. doi: 10.1152/physrev.1998.78.3.687
![]() |
[14] |
Hardeland R, Cardinali DP, Srinivasan V, et al. (2011) Melatonin – A pleiotropic, orchestrating regulator molecule. Prog Neurobiol 93: 350–384. doi: 10.1016/j.pneurobio.2010.12.004
![]() |
[15] |
Ambriz-Tututi M, Rocha-González HI, Cruz SL, et al. (2009) Melatonin: a hormone that modulates pain. Life Sci 84: 489–498. doi: 10.1016/j.lfs.2009.01.024
![]() |
[16] |
Masruha M, de Souza Vieira DS, Minett TS, et al. (2008) Low urinary 6-sulfatoxymelatonin concentrations in acute migraine. J Headache Pain 9: 221–224. doi: 10.1007/s10194-008-0047-5
![]() |
[17] |
Masruha MR, Lin J, de Souza Vieira DS, et al. (2010) Urinary 6-sulfatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache 50: 413–419. doi: 10.1111/j.1526-4610.2009.01547.x
![]() |
[18] |
Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. (2009) Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 119: 821–846. doi: 10.1080/00207450802328607
![]() |
[19] |
Srinivasan V, Lauterbach EC, Ho KY, et al. (2012) Melatonin in antinociception: its therapeutic applications. Curr Neuropharmacol 10: 167–178. doi: 10.2174/157015912800604489
![]() |
[20] |
Noseda R, Hernández A, Valladares L, et al. (2004) Melatonin-induced inhibition of spinal cord synaptic potentiation in rats is MT2 receptor-dependent. Neurosci Lett 360: 41–44. doi: 10.1016/j.neulet.2004.01.080
![]() |
[21] |
Laurido C, Pelissie T, Soto-Moyano R, et al. (2002) Effect of melatonin on rat spinal cord nociceptive transmission. Neuroreport 13: 89–91. doi: 10.1097/00001756-200201210-00021
![]() |
[22] |
Chen WW, Zhang X, Huang WJ. (2016) Pain control by melatonin: Physiological and pharmacological effects. Exp Ther Med 12: 1963–1968. doi: 10.3892/etm.2016.3565
![]() |
[23] |
Wilhelmsen M, Amirian I, Reiter RJ, et al. (2011) Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 51: 270–277. doi: 10.1111/j.1600-079X.2011.00895.x
![]() |
[24] |
Herrero JF, Laird JM, López-García JA (2000) Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol 61: 169–203. doi: 10.1016/S0301-0082(99)00051-9
![]() |
[25] | Akerstedt T, Gillberg M, Wetterberg L (1982) The circadian covariation of fatigue and urinary melatonin. Biol Psychiatry 17: 547–554. |
[26] |
Pardini M, Cordano C, Benassi F, et al. (2014) Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. Eur Neuropsychopharmacol 24: 939–944. doi: 10.1016/j.euroneuro.2014.02.010
![]() |
[27] |
San L, Arranz B (2008) Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 23: 396–402. doi: 10.1016/j.eurpsy.2008.04.002
![]() |
[28] |
Ismail SA, Mowafi HA (2009) Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg 108: 1146–1151. doi: 10.1213/ane.0b013e3181907ebe
![]() |
[29] |
Nava F, Carta G (2001) Melatonin reduces anxiety induced by lipopolysaccharide in the rat. Neurosci Lett 307: 57–60. doi: 10.1016/S0304-3940(01)01930-9
![]() |
[30] |
Wan Q, Man HY, Liu F, et al. (1999) Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci 2: 401–403. doi: 10.1038/8062
![]() |
[31] |
Comai S, Gobbi G (2014) Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci 39: 6–21. doi: 10.1503/jpn.130009
![]() |
[32] |
Bunney WE, Bunney BG (2000) Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacol 22: 335–345. doi: 10.1016/S0893-133X(99)00145-1
![]() |
[33] |
Quera Salva MA, Hartley S, Barbot F, et al. (2011) Circadian rhythms, melatonin and depression. Curr Pharm Des 17: 1459–1470. doi: 10.2174/138161211796197188
![]() |
[34] |
Srinivasan V, Brzezinski A, Pandi-Perumal SR, et al. (2011) Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuropsychopharmacol Biol Psychiatry 35: 913–923. doi: 10.1016/j.pnpbp.2011.03.013
![]() |
[35] | Rizzi M, Sarzi-Puttini P, Atzeni F, et al. (2004) Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? J Rheumatol 31: 1193–1199. |
[36] |
Wikner J, Hirsch U, Wetterberg L, et al. (1998) Fibromyalgia--a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol (Oxf) 49: 179–183. doi: 10.1046/j.1365-2265.1998.00503.x
![]() |
[37] | Press J, Phillip M, Neumann L, et al. (1998) Normal melatonin levels in patients with fibromyalgia syndrome. J Rheumatol 25: 551–555. |
[38] | Korszun A, Sackett-Lundeen L, Papadopoulos E, et al. (1999) Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 26: 2675–2680. |
[39] | Klerman EB, Goldenberg DL, Brown EN, et al. (2001) Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 86: 1034–1039. |
[40] |
Senel K, Baygutalp F, Baykal T, et al. (2013) Melatonin levels in premenopausal women with fibromyalgia syndrome. Rheumatol Int 33: 1609–1610. doi: 10.1007/s00296-011-2315-y
![]() |
[41] | Pernambuco AP, Schetino LP, Viana RS, et al. (2015) The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin Exp Rheumatol 33(Suppl 88): S14–19. |
[42] |
Caumo W, Hidalgo MP, Souza A, et al. (2019) Melatonin is a biomarker of circadian dysregulation and is correlated with major depression and fibromyalgia symptom severity. J Pain Res 12: 545–556. doi: 10.2147/JPR.S176857
![]() |
[43] |
Webb SM (1998) Fibromyalgia and melatonin: are they related? Clin Endocrinol (Oxf) 49: 161–162. doi: 10.1046/j.1365-2265.1998.00548.x
![]() |
[44] |
Musshoff U, Riewenherm D, Berger E, et al. (2002) Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus 12: 165–173. doi: 10.1002/hipo.1105
![]() |
[45] |
Citera G, Arias MA, Maldonado-Cocco JA, et al. (2000) The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 19: 9–13. doi: 10.1007/s100670050003
![]() |
[46] |
Acuna-Castroviejo D, Escames G, Reiter RJ (2006) Melatonin therapy in fibromyalgia. J Pineal Res 40: 98–99. doi: 10.1111/j.1600-079X.2005.00278.x
![]() |
[47] |
Hussain SA, Al-Khalifa II, Jasim NA, et al. (2011) Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 50: 267–271. doi: 10.1111/j.1600-079X.2010.00836.x
![]() |
[48] |
de Zanette SA, Vercelino R, Laste G, et al. (2014) Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 15: 40. doi: 10.1186/2050-6511-15-40
![]() |
[49] |
Castaño MY, Garrido M, Delgado-Adamez J, et al. (2018) Oral melatonin administration improves the objective and subjective sleep quality, increases 6-sulfatoxymelatonin levels and total antioxidant capacity in patients with fibromyalgia. J Appl Biomed 16: 186–191. doi: 10.1016/j.jab.2018.01.005
![]() |
[50] |
Castaño MY, Garrido M, Rodríguez AB, et al. (2019) Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia. Biol Res Nurs 21: 22–29. doi: 10.1177/1099800418811634
![]() |
[51] |
Sánchez-Domínguez B, Bullón P, Román-Malo L, et al. (2015) Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with Fibromyalgia. Mitochondrion 21: 69–75. doi: 10.1016/j.mito.2015.01.010
![]() |
[52] |
Fatima G, Das SK, Mahdi AA (2017) Some oxidative and antioxidative parameters and their relationship with clinical symptoms in women with fibromyalgia syndrome. Int J Rheum Dis 20: 39–45. doi: 10.1111/1756-185X.12550
![]() |
[53] |
Torres-Farfan C, Richter HG, Rojas-García P, et al. (2003) mt1 Melatonin receptor in the primate adrenal gland: inhibition of adrenocorticotropin-stimulated cortisol production by melatonin. J Clin Endocrinol Metab 88: 450–458. doi: 10.1210/jc.2002-021048
![]() |
[54] | Mahdi AA, Fatima G, Das SK, et al. (2011) Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J Biochem Biophys 48: 82–87. |
[55] |
McLean SA, Williams DA, Harris RE, et al. (2005) Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 52: 3660–3669. doi: 10.1002/art.21372
![]() |
[56] |
Bruno A, Micò U, Lorusso S, et al. (2013) Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. J Clin Psychopharmacol 33: 507–511. doi: 10.1097/JCP.0b013e31829057ae
![]() |
[57] |
Calandre EP, Slim M, Garcia-Leiva JM, et al. (2014) Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: an uncontrolled, 12-week, pilot study. Pharmacopsychiatry 47: 67–72. doi: 10.1055/s-0033-1363659
![]() |
[58] |
Finan PH, Goodin BR, Smith MT (2013) The association of sleep and pain: an update and a path forward. J Pain 14: 1539–1552. doi: 10.1016/j.jpain.2013.08.007
![]() |